Current and future treatments of osteoporosis in men

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 6, 2014, Pages 871-884

  Kaufman, Jean Marc ^a   Lapauw, Bruno ^a   Goemaere, Stefan ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bisphosphonates; Denosumab; Men; Odanacatib romosozumab; Osteoporosis; Strontium ranelate; Teriparatide; Testosterone; Therapy

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; GLUCOCORTICOID; ODANACATIB; PARATHYROID HORMONE[1-34]; ROMOSOZUMAB; STRONTIUM RANELATE; TESTOSTERONE; ZOLEDRONIC ACID; BIPHENYL DERIVATIVE; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTICLE; BONE DENSITY; CLINICAL TRIAL (TOPIC); CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FRAGILITY FRACTURE; HUMAN; HYPOGONADISM; MALE; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIPHENYL COMPOUNDS; BONE DENSITY CONSERVATION AGENTS; HUMANS; MALE; OSTEOPOROSIS; TERIPARATIDE;

EID: 84927940107     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.09.002     Document Type: Review

References (69)

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-33.
2. Harvey N, Dennison E, Cooper C. Osteoporosis: Impact on health and economics. Nat Rev Rheumatol 2010; 6: 99-105.
3. Kiebzak GM, Beirnart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162: 2217-22.
4. Papaioannou A, Kennedy CC, Ionnadis G, et al. The osteoporosis care gap in men with fragility fractures: The Canadian Multicentre Osteoporosis Study. Osteoporos Int 2008; 19: 581-7.
5. Curtis JR, McClure LA, Delzell E, et al. Population based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 2009; 24: 956-62.
6. Van Staa TP, Dennison EM, Leufkens HG, et al. Epidemiology of fractures in England and Wales. Bone 2001; 29: 517-22.
7. Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999; 84: 3431-4.
8. Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367: 2010-8.
9. Kaufman JM, Goemaere S. Osteoporosis in men. Best Pract Res Clin Endocrinol Metab 2008; 22: 787-812.
10. Johnell O, Kanis JA, Jonsson B, et al. The burden of hospitalised fractures in Sweden. Osteoporos Int 2005; 16: 222-8.
11. Orwig DL, Chan J, Magaziner J. Hip fracture and its consequences: Differences between men and women. Orthop Clin North Am 2006; 37: 611-22.
12. Kanis JA, On behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary healthcare level. Technical report. UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; 2008.
13. Looker AC,Wahner HW, Dunn WL, et al. Updated data on proximal femur bonemineral levels of US adults. Osteoporos Int 1998; 8: 468-89.
14. Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone 2008; 42: 467-75.
15. Kanis JA, Melton III LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-41.
16. Kanis JA, Bianchi G, Bilezikian JP, et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int 2011; 22: 2789-98.
17. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20: 1185-94.
18. Selby PL, Davies PL, Adams JE. Do men and women fracture bones at similar bone densities? Osteoporos Int 2000; 11: 153-7.
19. Adler RA. Osteoporosis in men: Recent progress. Endocrine 2013; 44: 40-6.
20. Seeman E. The pathogenesis of bone fragility in women and men. Lancet 2002; 359: 1841-50.
21. Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23: 279-302.
22. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocr Rev 2004; 25: 389-425.
23. Riggs BL, Melton III LJ, Robb RA, et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 2004; 19: 1945-54.
24. Riggs BL, Melton III LJ, Robb RA, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: Evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 2008; 23: 208-14.
25. Khosla S, Riggs BL, Atkinson EJ, et al. Effects of sex and age on bone microstructure at the ultradistal radius: A populationbased non-invasive in vivo assessment. J Bone Miner Res 2006; 21: 124-31.
26. Duan Y, Beck TJ,Wang XF, et al. Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. J Bone Miner Res 2003; 18: 1766-74.
27. Szulc P, Kaufman JM, Delmas P. Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int 2007; 18: 1451-61.
28. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87: 3656-66.
29. Van Pottelbergh I, Goemaere S, Kaufman JM. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 2003; 88: 3075-81.
30. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 2004; 89: 5898-6590.
31. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors and the skeleton. Endocr Rev 2008; 29: 535-59.
32. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-76.
33. Nguyen ND, Frost SA, Center JR, et al. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 2008; 18: 1109-17.
34. Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAXdassessment and intervention thresholds for the UK. Osteoporos Int 2008; 19: 1395-408.
35. Nelson B, Watts NB, Adler RA, et al. Osteoporosis in men: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 1802-22.
36. Johansson H, Kanis JA, McCloskey EV, et al. A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int 2011; 22: 453-61.
37. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008; 358: 1474-82.
38. London, Doc. Ref. CPMP/EWP/552/95 Rev. 2 Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. 2006.
39. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367: 1714-23.
40. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-10.
41. Drake WM, Kendler DL, Rosen CJ, et al. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 2003; 88: 5759-65.
42. Boonen S, Orwoll ES,Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: Results of a 2-year, placebocontrolled, double-blind, multicenter study. J Bone Miner Res 2009; 24: 719-25.
43. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-809.
44. Boonen S, Orwoll E, Magaziner J, et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 2011; 59: 2084-90.
45. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
46. Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010; 25: 2239-50.
47. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-55.
48. Orwoll E, Teglbjaerg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012; 97: 3161-9.
49. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34) ] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17.
50. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporos Int 2005; 16: 510-6.
51. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349: 1216-26.
52. Finkelstein JS, Leder BZ, Burnett SM, et al. Effect of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006; 91: 2882-7.
53. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-15.
54. Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH (1-34) ] in postmenopausal osteoporosis. J Bone Miner Res 2011; 26: 503-11.
55. Rizzoli R, Reginster J-Y, Boonen S, et al. Adverse reactions and drugedrug interactions in the management of women with osteoporosis. Calcif Tissue Int 2011; 89: 91-104.
56. Kaufman J-M, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 2013; 98: 592-601.
57. Anderson MS, Gendrano IN, Liu C, et al. Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenausal women. J Clin Endocrinol Metab 2014; 99: 552-60.
58. Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosizumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. J Clin Pharmacol 2014; 54: 168-78.
59. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370: 412-20.
60. McColm J, Hu L, Womack T, et al. Single-and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 2014; 29: 935-43.
61. Glantschnig H, Scott K, Hampton R, et al. A rate-limiting role for dickkopf-1in bone formationand the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther 2011; 338: 568-78.
62. Nemeth EF, Shoback D. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders. Best Pract Res Clin Endocrinol Metab 2013; 27: 373-84.
63. Mellstrom D, Vandenput L, Mallmim H, et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008; 23: 1552-60.
64. Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386-90.
65. Greenspan SL, Nelson JB, Trump DL, et al. Effect of once weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. Ann Intern Med 2007; 146: 416-24.
66. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-104.
67. Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 3841-6.
68. Rizzoli R, Adachi JD, Cooper C, et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2012; 91: 225-43.
69. Kaufman JM, Reginster JY, Boonen S, et al. Treatment of osteoporosis in men. Bone 2013; 53: 134-44.